PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY
Seok-Goo Cho,
Tae Min Kim,
Michał Taszner,
Tsai Yun Chen,
Aafia Chaudhry,
Melanie Ufkin,
Amulya Uppala,
Ayesha Sabir,
Hesham Mohamed,
Srikanth Ambati,
Emmanuel Bachy
Affiliations
Seok-Goo Cho
1 Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea, Rep. of South
Tae Min Kim
2 Seoul National University Hospital, Seoul, Korea, Rep. of South
Michał Taszner
3 Medical University of Gdańsk, Department of Haematology and Transplantology, Faculty of Medicine, Gdańsk, Poland
Tsai Yun Chen
4 National Cheng Kung University Hospital, Department of Internal Medicine, Tainan, Taiwan
Aafia Chaudhry
5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Melanie Ufkin
5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Amulya Uppala
5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Ayesha Sabir
5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Hesham Mohamed
5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Srikanth Ambati
5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Emmanuel Bachy
6 Lyon Sud Hospital, Department of Hematology, Lyon, France
